UOC
PVLA

UBS O'Connor’s Palvella Therapeutics PVLA Stock Holding History

UBS O'Connor’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,994
Closed -$992K – 469
2025
Q2 		$992K Sell
43,994
-4,670
-10% -$110K 0.03% 224
2025
Q1 		$1.36M Buy
+48,664
New +$938K 0.03% 158

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS O'Connor's PVLA Position: Q3 2025 in Review

UBS O'Connor sold out of Palvella Therapeutics (PVLA) in Q3 2025, closing a stake of 43,994 shares — an estimated $992K sold.

UBS O'Connor first reported a position in PVLA in Q1 2025 and held it in 2 quarters. The position peaked at $1.36M in Q1 2025. 100 funds tracked by Wall St. Rank hold PVLA as of Q3 2025.

  • UBS O'Connor reported no remaining Palvella Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 43,994 Palvella Therapeutics shares in Q3 2025, an estimated $992K.
  • UBS O'Connor first reported a position in Palvella Therapeutics in Q1 2025 and held it in 2 quarters.
  • UBS O'Connor's Palvella Therapeutics position peaked at $1.36M in Q1 2025.
  • 100 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.